All In Biotech

Drug Trial Radar · NCT06689163

A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

An Open, Multicenter Phase Ib/II Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Dec 11, 2024

Primary completion

Nov 30, 2025

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.

Conditions

  • Prostate Cancer

Interventions

  • HRS-1167 tabletsDrug

    HRS-1167 tablets

  • Abiraterone Acetate tablets(II)Drug

    Abiraterone Acetate tablets(II)

  • Prednisone Acetate tabletsDrug

    Prednisone Acetate tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: 28 days
  2. Recommended phase II dose (RP2D)Time frame: 28 days
  3. The dose suspension rate caused by drug-related adverse eventsTime frame: 2 years
  4. The dose downregulation rate caused by drug-related adverse eventsTime frame: 2 years
  5. The dose termination rate caused by drug-related adverse eventsTime frame: 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital Of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.